Despite owning multiple related businesses (e.g., in video), Bending Spoons deliberately avoids forcing synergies like cross-selling or bundling. They believe the value lost in organizational agility, ownership, and speed far outweighs the small potential revenue gains. This 'Procter & Gamble for tech' model allows each brand to operate with startup-like autonomy, preserving its unique value.

To innovate at scale, Harness treats each new product as a semi-independent entity. These "startups" have a founder-like PM, go through internal seed/Series A funding stages tied to revenue milestones (e.g., $1M ARR), and are responsible for their own initial founder-led sales.

The key to effective portfolio entrepreneurship isn't random diversification. It's about serving the same customer segment across multiple products. This creates a cohesive ecosystem where each new offering benefits from compounding knowledge and trust, making many things feel like one thing.

In a multi-product company, horizontal teams naturally prioritize mature, high-impact businesses. Structuring teams vertically with P&L ownership for each product, even nascent ones, ensures dedicated focus and accountability, preventing smaller initiatives from being starved of resources.

Rion structures itself as a central "hub" with core technology, then creates separate "spoke" companies for verticals like veterinary or cosmetics. These spokes raise their own targeted capital, allowing Rion to fund platform development without constant dilution at the parent company level and diversifying funding risk.

To launch new products and compete with agile startups, embed a small "incubation seller" team directly within the technology organization. This model ensures tight alignment between product, engineering, and the first revenue-generating efforts, mirroring the cross-functional approach of an early-stage company.

Single-product companies struggle to align R&D team size with fluctuating opportunities. Bending Spoons uses a centralized pool of flexible R&D talent that can be rapidly deployed to different portfolio companies, maximizing efficiency and capturing short-lived windows of opportunity that others miss.

An internal incubator’s biggest mistake is acting like an external startup. Finding product-market fit is insufficient. Lasting success requires achieving "product-company fit" by deeply understanding and aligning with the parent company's internal business units, strategic goals, and unique challenges.

To avoid the pitfalls of scale in R&D, Eli Lilly operates small, focused labs of 300-400 people. These 'internal biotechs' have mission focus and autonomy, while leveraging the parent company's scale for clinical trials and distribution.